Nifty
Sensex
:
:
15746.45
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)

Pharmaceuticals & Drugs - Veterinary

Rating :
61/99

BSE: 512529 | NSE: SEQUENT

308.65
27-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  304.90
  •  311.90
  •  292.00
  •  303.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1843866
  •  5578.61
  •  336.50
  •  109.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,536.82
  • 78.97
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,791.64
  • 0.16%
  • 10.36

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.86%
  • 6.92%
  • 19.28%
  • FII
  • DII
  • Others
  • 13.15%
  • 2.68%
  • 4.11%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.22
  • 13.54
  • 4.59

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.11
  • 24.60
  • 8.84

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.97
  • 15.48
  • -45.06

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 28.78
  • 32.76

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.72
  • 3.57
  • 4.05

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 59.17
  • 24.30
  • 18.25

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
361.82
300.58
20.37%
358.21
316.42
13.21%
346.27
284.22
21.83%
310.26
278.02
11.60%
Expenses
318.54
255.85
24.50%
291.91
266.44
9.56%
289.88
247.06
17.33%
259.25
239.57
8.21%
EBITDA
43.28
44.74
-3.26%
66.31
49.98
32.67%
56.39
37.16
51.75%
51.02
38.44
32.73%
EBIDTM
11.96%
14.88%
18.51%
15.80%
16.29%
13.07%
16.44%
13.83%
Other Income
1.37
1.83
-25.14%
2.81
0.98
186.73%
2.64
5.97
-55.78%
1.55
1.31
18.32%
Interest
3.18
9.33
-65.92%
6.20
9.60
-35.42%
7.36
7.84
-6.12%
7.65
8.95
-14.53%
Depreciation
12.68
13.09
-3.13%
11.58
13.05
-11.26%
13.30
12.46
6.74%
13.03
12.01
8.49%
PBT
29.01
24.14
20.17%
51.33
28.31
81.31%
29.32
22.83
28.43%
31.89
18.80
69.63%
Tax
5.49
5.91
-7.11%
11.64
4.25
173.88%
7.96
-1.64
-
7.42
3.50
112.00%
PAT
23.52
18.23
29.02%
39.69
24.06
64.96%
21.36
24.47
-12.71%
24.47
15.30
59.93%
PATM
6.50%
6.06%
11.08%
7.60%
6.17%
8.61%
7.89%
5.50%
EPS
0.83
0.68
22.06%
1.50
0.82
82.93%
0.86
0.86
0.00%
0.84
0.46
82.61%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,376.56
1,179.24
1,039.31
1,030.59
683.57
624.98
465.36
455.46
326.86
345.81
311.89
Net Sales Growth
16.73%
13.46%
0.85%
50.77%
9.37%
34.30%
2.17%
39.34%
-5.48%
10.88%
 
Cost Of Goods Sold
704.29
605.05
543.01
554.23
356.70
311.71
240.72
243.65
181.72
192.27
162.01
Gross Profit
672.27
574.19
496.30
476.36
326.87
313.27
224.65
211.81
145.14
153.53
149.87
GP Margin
48.84%
48.69%
47.75%
46.22%
47.82%
50.12%
48.27%
46.50%
44.40%
44.40%
48.05%
Total Expenditure
1,159.58
1,008.92
914.37
919.10
643.03
568.27
444.87
438.68
342.51
308.74
266.39
Power & Fuel Cost
-
24.73
23.06
14.66
12.77
26.51
23.32
22.06
23.53
20.21
16.75
% Of Sales
-
2.10%
2.22%
1.42%
1.87%
4.24%
5.01%
4.84%
7.20%
5.84%
5.37%
Employee Cost
-
165.06
145.95
132.07
106.22
88.62
62.39
48.12
41.47
29.40
29.82
% Of Sales
-
14.00%
14.04%
12.81%
15.54%
14.18%
13.41%
10.57%
12.69%
8.50%
9.56%
Manufacturing Exp.
-
83.24
77.73
59.07
57.63
72.14
54.31
52.30
41.42
27.88
33.72
% Of Sales
-
7.06%
7.48%
5.73%
8.43%
11.54%
11.67%
11.48%
12.67%
8.06%
10.81%
General & Admin Exp.
-
56.37
58.35
70.92
48.60
36.44
33.79
43.58
23.96
13.69
15.95
% Of Sales
-
4.78%
5.61%
6.88%
7.11%
5.83%
7.26%
9.57%
7.33%
3.96%
5.11%
Selling & Distn. Exp.
-
45.16
36.29
36.87
28.78
17.46
20.27
12.30
10.51
9.23
7.52
% Of Sales
-
3.83%
3.49%
3.58%
4.21%
2.79%
4.36%
2.70%
3.22%
2.67%
2.41%
Miscellaneous Exp.
-
29.32
29.98
51.29
32.34
15.40
10.07
16.66
19.91
16.05
7.52
% Of Sales
-
2.49%
2.88%
4.98%
4.73%
2.46%
2.16%
3.66%
6.09%
4.64%
0.20%
EBITDA
217.00
170.32
124.94
111.49
40.54
56.71
20.49
16.78
-15.65
37.07
45.50
EBITDA Margin
15.76%
14.44%
12.02%
10.82%
5.93%
9.07%
4.40%
3.68%
-4.79%
10.72%
14.59%
Other Income
8.37
10.09
8.67
17.20
11.08
14.30
9.96
3.84
4.96
10.48
6.69
Interest
24.39
35.71
32.80
39.70
28.34
38.56
44.37
39.04
33.45
29.99
23.80
Depreciation
50.59
50.62
41.92
53.30
40.07
46.22
32.94
32.60
28.61
22.98
20.69
PBT
141.55
94.08
58.88
35.70
-16.80
-13.77
-46.85
-51.00
-72.75
-5.41
7.69
Tax
32.51
12.03
2.01
13.46
-0.41
2.62
3.39
0.58
-8.06
-3.95
7.51
Tax Rate
22.97%
12.79%
3.41%
3.03%
2.44%
-19.03%
-40.50%
-0.53%
11.08%
73.01%
215.80%
PAT
109.04
69.91
48.66
421.57
-13.83
-18.47
-10.74
-110.49
-64.69
-1.40
-0.17
PAT before Minority Interest
100.04
82.05
56.88
430.83
-16.39
-16.39
-11.76
-110.49
-64.69
-1.46
-4.02
Minority Interest
-9.00
-12.14
-8.22
-9.26
2.56
-2.08
1.02
0.00
0.00
0.06
3.85
PAT Margin
7.92%
5.93%
4.68%
40.91%
-2.02%
-2.96%
-2.31%
-24.26%
-19.79%
-0.40%
-0.05%
PAT Growth
32.88%
43.67%
-88.46%
-
-
-
-
-
-
-
 
EPS
4.39
2.81
1.96
16.97
-0.56
-0.74
-0.43
-4.45
-2.60
-0.06
-0.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
742.76
706.69
647.58
976.79
945.71
91.27
56.73
95.00
122.53
123.06
Share Capital
49.67
49.37
48.75
48.75
47.65
30.48
26.74
23.44
21.34
21.23
Total Reserves
679.00
638.43
581.25
912.49
874.01
26.85
-0.37
59.68
101.19
101.82
Non-Current Liabilities
241.56
214.75
227.13
246.20
299.72
277.55
159.23
144.35
104.79
123.22
Secured Loans
107.97
126.94
85.14
141.76
197.50
249.97
150.52
137.32
80.19
90.73
Unsecured Loans
42.09
20.90
18.40
23.38
13.82
0.35
0.56
0.72
0.88
8.46
Long Term Provisions
13.16
30.50
28.54
34.76
28.66
25.70
8.03
6.09
15.49
11.74
Current Liabilities
479.57
440.41
430.93
663.55
290.37
406.09
405.28
345.41
329.56
199.21
Trade Payables
220.38
209.35
160.49
203.04
143.94
90.94
114.59
150.91
123.94
82.61
Other Current Liabilities
92.65
87.80
106.52
259.26
83.23
107.43
56.80
35.63
75.38
37.71
Short Term Borrowings
134.36
127.36
152.41
194.70
56.04
204.31
226.60
151.76
123.34
69.09
Short Term Provisions
32.19
15.90
11.51
6.54
7.17
3.42
7.29
7.12
6.89
9.80
Total Liabilities
1,508.63
1,402.10
1,342.62
1,903.76
1,538.02
921.84
625.82
589.34
562.37
446.25
Net Block
632.23
498.14
475.97
684.33
586.48
474.43
237.59
227.26
229.76
210.76
Gross Block
818.12
638.06
581.74
789.60
643.70
596.25
369.07
330.69
305.11
264.26
Accumulated Depreciation
185.89
139.91
105.77
105.27
57.22
121.82
131.48
103.43
75.35
53.50
Non Current Assets
794.52
795.99
804.61
1,176.02
1,047.48
612.00
359.87
358.31
351.94
282.23
Capital Work in Progress
13.42
22.61
18.04
32.55
23.52
39.06
43.04
88.71
64.07
19.53
Non Current Investment
131.29
179.65
221.73
363.97
360.58
58.04
0.04
1.64
0.04
0.05
Long Term Loans & Adv.
14.40
32.27
31.01
37.51
30.35
36.01
76.06
39.28
55.77
50.87
Other Non Current Assets
3.18
63.31
57.86
57.66
46.54
4.47
3.15
1.42
2.30
1.02
Current Assets
714.11
606.12
538.01
727.74
490.54
309.84
265.94
231.04
210.42
164.02
Current Investments
40.18
0.47
17.34
64.12
66.98
0.58
0.08
0.18
0.28
0.33
Inventories
219.42
200.10
158.57
160.81
135.08
94.36
101.40
85.62
68.24
65.55
Sundry Debtors
318.76
278.25
258.35
254.62
192.39
115.44
83.54
65.81
70.41
55.45
Cash & Bank
75.83
72.04
42.45
47.40
25.30
38.46
36.21
33.00
35.88
9.17
Other Current Assets
59.92
8.51
5.25
146.31
70.80
61.01
44.71
46.44
35.62
33.52
Short Term Loans & Adv.
44.41
46.75
56.05
54.48
46.69
41.86
37.47
36.48
28.84
31.25
Net Current Assets
234.54
165.71
107.08
64.19
200.17
-96.25
-139.34
-114.37
-119.13
-35.19
Total Assets
1,508.63
1,402.11
1,342.62
1,903.76
1,538.02
921.84
625.81
589.35
562.36
446.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
115.33
116.02
45.24
-7.19
-0.05
-23.55
-44.78
-3.82
21.48
49.63
PBT
94.08
58.88
445.79
-16.80
-13.77
-8.37
-109.91
-72.75
-5.41
3.49
Adjustment
91.41
84.47
-313.85
123.31
83.81
35.92
133.52
65.98
46.98
36.77
Changes in Working Capital
-58.30
-27.95
-77.87
-104.37
-71.46
-53.98
-67.45
2.48
-17.29
15.96
Cash after chg. in Working capital
127.18
115.40
54.06
2.14
-1.42
-26.44
-43.84
-4.28
24.27
56.22
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-11.85
0.62
-8.83
-9.33
1.37
2.89
-0.95
0.46
-2.79
-6.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-72.27
-67.69
7.17
-116.18
-315.83
-154.69
-79.95
-54.89
-66.78
-71.77
Net Fixed Assets
-29.66
-32.63
221.87
-49.63
97.97
38.51
-26.62
-28.82
-41.67
-80.90
Net Investments
30.56
-101.61
210.25
0.26
-713.97
-118.07
-10.37
-15.66
-25.20
31.50
Others
-73.17
66.55
-424.95
-66.81
300.17
-75.13
-42.96
-10.41
0.09
-22.37
Cash from Financing Activity
-42.75
-20.08
-56.96
147.44
308.69
179.41
145.54
34.70
61.94
16.51
Net Cash Inflow / Outflow
0.31
28.25
-4.55
24.07
-7.19
1.17
20.80
-24.02
16.63
-5.62
Opening Cash & Equivalents
67.79
39.54
44.10
20.03
21.85
22.96
3.45
27.37
9.17
14.07
Closing Cash & Equivalent
68.10
67.79
39.54
44.10
20.03
21.83
22.96
3.45
27.37
9.17

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
29.34
27.86
25.85
39.44
38.69
3.76
1.97
7.09
11.48
11.59
ROA
5.64%
4.14%
26.54%
-0.95%
-1.33%
-1.52%
-18.19%
-11.23%
-0.29%
-0.97%
ROE
11.58%
8.63%
54.15%
-1.74%
-3.35%
-28.10%
-201.83%
-62.91%
-1.19%
-3.42%
ROCE
12.33%
9.24%
41.28%
0.87%
2.72%
6.93%
-16.09%
-9.86%
6.98%
9.11%
Fixed Asset Turnover
1.65
1.74
1.51
0.96
1.03
1.01
1.36
1.08
1.26
1.31
Receivable days
90.45
92.53
90.49
118.40
87.75
74.80
57.30
72.70
64.08
63.08
Inventory Days
63.56
61.85
56.34
78.37
65.41
73.58
71.75
82.12
68.11
69.36
Payable days
80.87
75.36
77.04
104.11
77.28
87.31
115.68
149.32
123.09
94.20
Cash Conversion Cycle
73.14
79.02
69.78
92.66
75.87
61.07
13.36
5.51
9.10
38.25
Total Debt/Equity
0.45
0.47
0.48
0.43
0.34
8.26
15.86
3.74
2.19
1.54
Interest Cover
3.63
2.80
12.19
0.41
0.64
0.81
-1.82
-1.18
0.82
1.15

News Update:


  • SeQuent Scientific gets EUGMP approval for tablets dosage manufacturing line in Turkey
    15th Jul 2021, 09:23 AM

    The company has already embarked upon significant expansion in Turkey to meet the growing requirements of the local market

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.